TMCnet News
W2O Group Appoints Angela Gillespie Chief Strategy Officer of Its Global MedTech PracticeW2O Group, a network of complementary integrated marketing and communications firms powered by analytics and insights, announced today that it has named Angela Gillespie Chief Strategy Officer of its Global MedTech Practice, which has been a cornerstone of the firm's legacy healthcare offering. Gillespie, who started the agency's medical device practice in 2007, has rejoined the firm in its Minneapolis office after working in house as a marketing executive at leading innovative medical device companies for the last several years. She has 20 years of agency and in-house experience most recently as Vice President of Marketing for NeuWave Medical (recently acquired by J&J) and Senior Market Development Leader for Covidien's Peripheral and Venous Vascular Business divisions (acquired by Medtronic in 2015). Her remit is to double the firm's partnerships with MedTech companies over the next five years. In this newly created role, she will drive strategy, operations and alignment of the medical device portfolio and offering across all W2O Group agencies. "With the confluence of personalized medicine, digital health and medical device and diagnostics, the MedTech sector is poised to grow at a faster CAGR than big pharma in large part due to the significant impact these companies will have in managing and treating healthcare globally in the next decade," said Jennifer Gottlieb, W2O Group's Chief Client Service Officer. "We plan to leverage our unique expertise and talent in this area to become a partner of choice for the best firms in this spac. Angela is a proven leader who knows the space cold and will galvanize our offering and apply our integrated approach to support marketers and the C-suite in a way we believe no other consulting firm can." W2O Group is one of the only marketing communications firm with a focused integrated business solution offering in the medical device sector with teams clustered across anchor offices in San Francisco, Minneapolis, Boston and London. "We define MedTech as how technology is utilized to improve health care, whether it is a medical device or diagnostic, a new software platform or an app, our focus is on helping our clients realize the accessible benefits their technologies provide for patients globally," said Gillespie. "As the industry moves from a fee-for-service to a fee-for-performance model, we will continue to experience an explosive innovation shift fueling breakthroughs in wearable, sensor and implantable technology and personalized data management that will require our MedTech teams to be experts in cardiology or code in order to help our clients successfully transform healthcare outcomes. Given our team's legacy in this space and our acute understanding of the changes ahead, I am excited to lead our MedTech teams as we support our clients in achieving the market success they are uniquely poised to realize."
About W2O Group
Follow W2O Group on Twitter
View source version on businesswire.com: http://www.businesswire.com/news/home/20160727005448/en/ |
